Psychocare Health Pvt. Ltd. (PCHPL), a leading Neuropsychiatry PCD Pharma Company in India, has announced a landmark Master Collaboration Agreement with Novo Integrated Sciences, Inc. (NASDAQ: NVOS). This strategic partnership aims to bring cutting-edge healthcare, nutraceutical, and dietary solutions to both the Indian and North American markets, showcasing PCHPL’s growing global presence.
This collaboration reflects the shared vision of both companies to enhance global access to innovative and science-backed healthcare products. The partnership enables PCHPL to launch exclusive products developed by Novo in the Indian market, while also distributing PCHPL’s extensive range of pharmaceutical and nutraceutical offerings in North America.
With a strong presence and a network of 500+ distributors across India, PCHPL is poised to further strengthen its position in the Neuropsychiatry PCD Pharma Franchise business.
Leadership Speaks
Robert Mattacchione, CEO and Chairman of Novo Integrated Sciences, expressed optimism about the collaboration:
“This partnership aligns with our mission to expand our global footprint and deliver innovative healthcare solutions. PCHPL’s impressive growth and product range make it an ideal partner to achieve significant market impact.”
Mr. Supreet Singh, CEO of PCHPL, highlighted the importance of the agreement:
“This collaboration marks a major milestone in our journey to becoming a global healthcare player. Novo’s innovative capabilities will strengthen our product offerings and support our vision of delivering affordable, high-quality healthcare worldwide.”
The initial focus will be on products related to the central nervous system, gastrointestinal health, and protein-based supplements—key areas of growth in the Indian market. The collaboration supports the projected boom in India’s dietary supplements market, which is expected to reach INR 491.4 billion by 2032, growing at a CAGR of 13.49% (IMARC Group).
The agreement is valid for three years, with the option for renewal through mutual consent.
PCHPL: From Local Roots to Global Reach
Founded as Radix Pharmaceuticals in 2005, PCHPL has evolved into a trusted name in the Indian healthcare sector. Under the leadership of Mr. Jagdeep Singh and Mr. Supreet Singh, the company now offers over 900 products across segments, including:
- Pharmaceuticals & Nutraceuticals
- Neuropsychiatry & Dermatology
- Cosmetics & Ayurvedic Medicines
- Protein and dietary supplements
PCHPL is also exploring advanced healthcare technologies and Ayurveda/Siddha/Unani therapies to cater to diverse healthcare needs.
Awards & Recognition
- 40 Under 40 – Business Outreach Magazine (2023) for Innovation & Resilience – Supreet Singh
- MSME India Business Awards (2022, 2023)
- Brand Impact Award – Indian Achievers Forum (2021-22)
- India’s Fastest Growing Healthcare Company – CIMS Medica (2021) in Neuro & Psychiatry
Innovations Beyond Pharma: The Supreet Singh Show & Cancare Inc.
Apart from leading PCHPL, Mr. Supreet Singh is a certified broadcaster from Vancouver and host of The Supreet Singh Show, a growing podcast platform that highlights inspiring journeys and impactful stories.
PCHPL is also expanding into Canada through Cancare Inc., along with launching a dedicated e-commerce platform, solidifying its international ambitions.
About Novo Integrated Sciences, Inc.
Novo is transforming healthcare delivery with its patient-first, technology-driven, and multi-disciplinary approach. Their decentralized healthcare model focuses on:
- Service Networks
- Innovative Technology
- Holistic Health Products
Novo’s mission is to make non-catastrophic healthcare more efficient and accessible through strategic global partnerships like the one with PCHPL.
